Metraipolis › archive › dc_c0eafffeab6e

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation — Europe PMC PMID:41204558

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41204558
DOI
10.1097/md.0000000000045702
License (as archived)
solo-consultazione
Archived
2026-11-08T21:02:26.515Z
SHA-256 of the archived text
f9c9608af4810dcea333355388e1191b252a6a75f110f29f820b0bd84b1afb2d
Stable URL of this page
https://metraipolis.com/documento/dc_c0eafffeab6e

How to cite

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation — Europe PMC PMID:41204558 — Europe PMC (en), https://europepmc.org/article/MED/41204558 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c0eafffeab6e (Metraipolis archive dc_c0eafffeab6e, sha256 f9c9608af4810dcea333355388e1191b252a6a75f110f29f820b0bd84b1afb2d)
BibTeX
@misc{dcc0eafffeab6e,
  title = {Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation — Europe PMC PMID:41204558},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41204558},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c0eafffeab6e; sha256 f9c9608af4810dcea333355388e1191b252a6a75f110f29f820b0bd84b1afb2d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41204558. Agents can read the archived copy with the MCP tool read_document.